Janssen Sciences Ireland Uc

🇮🇪Ireland

Country: 🇮🇪Ireland

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Active:61

Completed:25

Trial Phases

3 Phases

Phase 1:73

Phase 2:9

Phase 3:3

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (85 trials with phase data)• Click on a phase to view related trials

Phase 1

73 (85.9%)

Phase 2

9 (10.6%)

Phase 3

3 (3.5%)

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

Conditions: Respiratory Syncytial Virus

First Posted Date: 2020-01-09

Last Posted Date: 2022-08-29

Lead Sponsor: Janssen Sciences Ireland UC

Registration Number: NCT04221412

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: JNJ-56136379

First Posted Date: 2019-12-23

Last Posted Date: 2021-04-20

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 16

Registration Number: NCT04208399

Locations: 🇩🇪
APEX GmbH, Munchen, Germany

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: JNJ-73763989

First Posted Date: 2019-12-23

Last Posted Date: 2020-09-30

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 16

Registration Number: NCT04208386

Locations: 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Phase 2

Completed

Conditions: Hepatitis B, Chronic

Interventions: Drug: JNJ-73763989
Drug: Placebo for JNJ-73763989
Drug: Placebo for JNJ-56136379
Drug: JNJ-56136379
Drug: Entecavir (ETV) monohydrate
Drug: Tenofovir disoproxil fumarate (TDF)
Drug: Tenofovir alafenamide (TAF)

First Posted Date: 2019-10-17

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 130

Registration Number: NCT04129554

Locations: 🇧🇪
Cliniques Universitaires Saint Luc, Bruxelles, Belgium
🇧🇪
SGS Belgium NV, Edegem, Belgium
🇧🇪
UZ Antwerpen, Edegem, Belgium

and more 38 locations

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

Phase 2

Terminated

Conditions: Respiratory Syncytial Virus Infections

Interventions: Drug: JNJ-53718678 250 mg
Drug: Placebo
Drug: JNJ-53718678 125 mg

First Posted Date: 2019-08-14

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Sciences Ireland UC

Target Recruit Count: 3

Registration Number: NCT04056611

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Henry Ford Hospital - Hematology/oncology, Detroit, Michigan, United States
🇺🇸
University Of Minnesota, Minneapolis, Minnesota, United States

and more 66 locations

News

No news found

AI-Powered Research

Premium Access

Janssen Sciences Ireland Uc

Clinical Trials

Trial Phases

Drug Approvals

Drug Approvals

Clinical Trials

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

News